Research programme: macrocyclic peptide therapeutics - Circle Pharma

Drug Profile

Research programme: macrocyclic peptide therapeutics - Circle Pharma

Alternative Names: Cancer therapeutics - Circle Pharma; CyclinA/Cdk2-targeting molecules - Circle Pharma; MCL1-targeting molecules - Circle Pharma

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Circle Pharma
  • Class Antineoplastics; Macrocyclic compounds; Peptides
  • Mechanism of Action Cyclin modulators; Cyclin-dependent kinase 2 modulators; Intracellular signalling peptide and protein inhibitors; MCL1 protein modulators; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 12 Sep 2016 Circle Pharma enters agreement with Pfizer to build a library of macrocyclic peptides
  • 30 Sep 2014 Research programme: macrocyclic peptide therapeutics - Circle Pharma is available for licensing as of 24 Sep 2014.
  • 01 Jun 2014 Early research in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top